November 9th, 2026Asundexian Receives FDA Approval for Secondary Stroke PreventionThe FDA approved asundexian with antiplatelet therapy after noncardioembolic ischemic stroke or high-risk TIA, based on OCEANIC-STROKE data.Read more
November 7th, 2026Asundexian Effect Consistent Across Vascular Risk Levels in OCEANIC-STROKEAsundexian lowered ischemic stroke without more major bleeding across low, intermediate, and high Framingham risk groups (all P interaction > .25).Read more
November 10th, 2026Don't Miss a Beat: What Lp(a)HORIZON and ZEUS Teach About Clinical Trial ScienceLp(a)HORIZON and ZEUS hit their biomarker targets but not MACE. Stephen Greene, MD, and Muthiah Vaduganathan, MD, MPH, unpack both at AHA 2026.Read more
November 8th, 2026Lp(a)HORIZON, Oral PCSK9s, and 2027 Lipid Trials, with Kausik Ray, MD, MBChB, MPhilKausik Ray, MD, MBChB, MPhil, discusses Lp(a)HORIZON, remnant cholesterol targets, enlicitide, and the lipid outcome trials to watch in 2027.Read more
November 8th, 2026SHASTA-3/4: Plozasiran Could Cut Acute Pancreatitis Risk by 78% Across sHTG SpectrumIn 757 adults with severe hypertriglyceridemia, plozasiran cut acute pancreatitis events by 78% overall and 91% in those with recent prior pancreatitis.Read more
November 7th, 2026Ez-PAVE: Initial Statin-Ezetimibe Combination No Better than Statins AloneWith LDL-C target-guided titration, starting statin plus ezetimibe vs a statin alone yielded similar 3-year events in ASCVD.Read more
November 7th, 2026STREAM: Statin Discontinuation Noninferior in Older Adults Without CVDStopping statins was noninferior at 2 years in adults 70 and older without CVD, but events were higher over full follow-up (12.7% vs 9.2%).Read more
November 7th, 2026Common Diuretic Linked to Home Blood Pressure Lowering After StrokeAdding spironolactone lowered 3-month home SBP by 7.7 mm Hg vs standard care in 160 stroke survivors with uncontrolled hypertension.Read more